Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intravenous zanamivir versus oral oseltamivir in hospitalized influenza
NL-OMON36811Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zanamivir and oseltamivir in influenza (3 arms), sponsored by GSK. Primary endpoint: Time to clinical response. Started Jan 2013; status: recruiting.
02
Drugs
zanamiviroseltamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON36811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36811.